A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult Participants

• Risankizumab (Drug), also known as SKYRIZI, ABBV-066: Subcutaneous Injection

Primary outcomes

• Maximum Observed Plasma Concentration (Cmax) of Risankizumab [Up to approximately 140 days]: Maximum observed plasma concentration (Cmax) of Risankizumab
• Time to Cmax (Tmax) of Risankizumab [Up to approximately 140 days]: Tmax of Risankizumab
• Apparent Terminal Phase Elimination Rate Constant (β) of Risankizumab [Up to approximately 140 days]: Apparent terminal phase elimination rate constant (β) of Risankizumab
• Terminal Phase Elimination Half-life (t1/2) of Risankizumab [Up to approximately 140 days]: Terminal phase elimination half-life (t1/2) of Risankizumab
• Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Last Measurable Concentration (AUCt) of Risankizumab [Up to approximately 140 days]: AUCt of Risankizumab
• Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Infinity (AUCinf) of Risankizumab [Up to approximately 140 days]: AUCinf of Risankizumab
• Number of Anti-drug antibody (ADA) Titers [Up to approximately 140 days]: Incidence and concentration of anti-drug antibodies
• Number of Participants Experiencing Adverse Events [Up to approximately 140 days]: An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment

Sex: All, ages: 18 Years to 60 Years, accepts healthy volunteers

Inclusion Criteria:

* Body Mass Index (BMI) ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at the time of screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
* Body weight greater than 40 kg and less than 100 kg at screening.
* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead ECG

Exclusion Criteria:

* Previous exposure to any anti-interleukin-12/23 or anti interleukin-23 treatment for at least one year prior to Screening.
* Intention to perform strenuous exercise to which the participant is unaccustomed within one week prior to administration of first dose of study drug and during the study.

• ABBVIE INC., Study director, AbbVie